TL;DR: Metformin’s glucose-lowering effect depends on a brain signaling pathway—it inhibits Rap1 in the hypothalamus, activating neurons that tell the liver to stop overproducing glucose. For decades, metformin has been the first-line drug for type 2 diabetes, working so reliably that millions take it daily. Yet its precise mechanism—how it actually lowers blood sugar—has remained …
TL;DR: Lecanemab, the first Alzheimer’s antibody to slow cognitive decline, works by activating immune cells called microglia through a specific immune signaling pathway, with the molecule SPP1/osteopontin playing a critical role in triggering the brain’s own cleanup machinery. When lecanemab was approved by the FDA, it sparked hope but also raised a fundamental question: how …
TL;DR: Untreated depression increases miscarriage risk by 34% across nearly 9 million women, but antidepressants reduce that risk to 24%—meaning the medication is safer than the disease during pregnancy. For decades, obstetricians have asked the wrong question about depression in pregnancy. They worried: Is the antidepressant dangerous? New data suggests a more sobering reality—the untreated …
TL;DR: Using PET imaging to directly visualize AMPA receptors in the living human brain, researchers discovered that ketamine’s rapid antidepressant effect works by reshuffling these receptors across specific brain regions in patients with treatment-resistant depression — and where they go predicts who will respond to the drug. Nearly one in three people with depression fail …
TL;DR: Blocking DUSP6 protein alongside ketamine extends antidepressant effects from 2 weeks to 4+ weeks in mice, potentially offering single-dose treatment instead of repeated infusions. Ketamine works like almost nothing else in psychiatry. A single infusion can lift severe depression within hours, even in patients who’ve failed every other drug. The problem? The magic doesn’t …
TL;DR: Chemists designed a new psilocin derivative with fluorine modifications that induces sub-hallucinogenic effects in mice, sidestepping the acute psychological effects of classic psychedelics while retaining therapeutic serotonin receptor activity. Psilocybin has emerged as a clinical darling—mounting evidence shows rapid relief for depression, anxiety, and cluster headaches. But there’s a catch: the intense hallucinations and …
TL;DR: A psychedelic drug that activates serotonin receptors dramatically amplifies slow 5-Hz brain oscillations in visual and memory regions, suggesting a mechanism for how hallucinogens distort perception by letting internal signals override external reality. Visual perception feels stable, seamless, continuous. But that stability is an illusion orchestrated by your brain. What neuroscientists have long wondered …
TL;DR: Diabetes and depression form a vicious cycle: high blood sugar triggers neuroinflammation and HPA axis dysfunction that cause depression, while depression sabotages blood sugar control through behavioral and metabolic pathways. Doctors have known for years that depression and type 2 diabetes often occur together. A patient in the clinic with uncontrolled blood sugar frequently …
TL;DR: Blocking opioid receptors with naltrexone reduces ketamine’s antidepressant effect by 28%, suggesting the opioid system is essential for ketamine to work. Ketamine is one of psychiatry’s great paradoxes: a club drug and anesthetic that can lift severe depression within hours where conventional antidepressants fail over months. Yet the mechanism remains mysterious. Recent research suggests …
This study found that individuals with the AG/GG genotype of the A118G SNP in the OPRM1 gene experienced more pleasant and fewer unpleasant effects from hydromorphone compared to those with the AA genotype, suggesting genotype-based differences in opioid sensitivity. Highlights: Positive Effects: Participants with the AG/GG genotype reported significantly more positive effects (e.g., good effects, …
